The mission of the Biosafety Core is two-fold. First and foremost, the core provides a fully managed, equipped, and safe working environment for the study of HIV, Mycobacterium tuberculosis (MTB) and other infectious pathogens. Secondly, the core actively develops state-of-the-art molecular methodologies for assessment of host/pathogen interactions for translational applications, such as the development of real-time quantitative PCR methodologies for the study of HIV replication and diversity in research samples. In addition, the core personnel have assumed the responsibility for training all users in good laboratory practices, periodic retraining to assure compliance with laboratory regulations, and providing services to promote research by all investigators in the CWRU/UHC research community. Dedicated BL-3 and BL-2+ laboratories are located across from each other on the 10th floor of the Biomedical Research Building in the Division of Infectious Diseases. A five-member Biosafety Committee meets to supervise safety procedures, and a six-member Scientific Team meets to determine developmental direction by the core on a quarterly basis. The activities of this core are essential to the success of CFAR, as both safety in investigation of biohazardous pathogens and development of new methodologies to assess host/HIV interactions constitute key elements in the AIDS research efforts at CWRU/UHC. The unique aspects of the core (i.e., the ability to study the interaction between HIV and virulent Mycobacterium tuberculosis), underscores the importance of this core as a major research strength of the CWRU/UHC CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-14
Application #
7491113
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
14
Fiscal Year
2007
Total Cost
$213,838
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773

Showing the most recent 10 out of 539 publications